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EDITORIAL
Dose intensity in cancer chemotherapy
D.J. Dodwell, H. Gurney & N. Thatcher
CRC Dept ofMedical Oncology, Christie Hospital, Wilmslow Road, Manchester M20 9BX, UK.
There is substantial evidence that, for the majority of anti-
tumour agents including alkylating agents, anthracycline
antibiotics and anti-metabolites, there is a steep dose res-
ponse curve when these agents are studied in in vitro and in
vivo models (Griswold et al., 1963; Bruce et al., 1966;
Schabel et al., 1984). It is this dose-response relationship
which is often cited in support of high dose chemotherapy
with autologous bone marrow rescue as a promising avenue
for the treatment of solid tumours. The purpose of this
review is to assess the evidence that dose and dose intensity
are important determinants of outcome in the treatment of
human cancer with cytotoxic chemotherapy. We will review
retrospective and prospective studies of dose and dose inten-
sity in a variety of tumour types, and discuss how future
clinical studies may be planned and presented to provide a
more informed therapeutic rationale for exposing patients to
greater doses of cytotoxic drugs in an attempt to improve
outcome.
Retrospective dose intensity analysis
Breast cancer
In 1984 Hryniuk and Bush analysed the complete and partial
remission rates and median survival times of 26 published
studies using CMF-type regimens in the treatment of
advanced breast cancer. For each regimen they also cal-
culated the average relative dose intensity in the following
way.
The doses of cyclophosphamide, methotrexate and 5-fluor-
ouracil were converted to a standard form of mgm2 per
week. The dose intensities of each agent were compared to
the dose intensity of a regimen used by Cooper (1969). The
dose intensities of the test regimen were expressed as a
fraction of the intensities of each drug in the Cooper proto-
col. The relative dose intensities for each drug in an individ-
ual CMF regimen were then averaged to give the average
relative dose intensity (ARDI) of CMF-containing therapy
for that particular 'test' regimen. They found a linear rela-
tionship between response rate and ARDI (Figure 1). The
relationship was even more clearcut when doses actually
delivered to patients, rather than planned protocol doses,
were used to calculate ARDI (Figure 1).
When the ARDI of a variety of CAF (cyclophosphamide,
doxorubicin and 5-fluorouracil) regimens were calculated in
the same way and expressed as a fraction of the ARDI of a
dose intensive 'reference' regimen used by Bull and Tormey
(1978) again there was a clear positive correlation between
ARDI and response rate and again the relationship was
clearer when delivered, rather than planned, doses were used.
Hryniuk and Bush also extended their observations to
median survival time. The median survival time (MST) (of all
patients) and the remission rates in these studies (CMF and
CAF) displayed a shallow positive relationship between
remission rate and MST. If one extends their observations
Correspondence: D.J. Dodwell.
Received: 19 January 1990.
and plots ARDI against MST then there is a shallow positive
relationship for the CAF regimens but no discernable rela-
tionship between ARDI and MST for the CMF type
regimens (Figure 2).
It is important to understand the assumptions that were
made in these analyses: (a) that cyclophosphamide, metho-
trexate, doxorubicin and 5-fluorouracil had equivalent activ-
ity against breast cancer and (b) that scheduling ofdrugs and
methods of administration were unimportant. They also did
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Figure 1 a, Relationship between average relative dose intensity
ARDI (planned doses) and response rate for CMF-containing
regimens analysed by Hryniuk and Bush (1984). b, Relationship
between ARDI and response rates where delivered doses were
used to calculate ARDI.
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Figure 2 a, Relationship between ARDI and median survival
time (MST) (months) for CMF-containing regimens (n.s.). b,
Relationship between ARDI and MST for CAF regimens (modi-
fied with permission from Hryniuk and Bush (1984)) (P<0.05).
not take into account the contribution of prednisolone and
vincristine (which were used in some of the studies) to cal-
culate ARDI.
1986 Hryniuk and Levine went on to analyse the relation-
ship between the ARDI of CMF-type adjuvant chemother-
apy regimens, used to treat patients after primary treatment
for stage II breast cancer, and 3 year relapse-free survival
(RFS). They restricted their analysis to trials which were
prospectively randomised and calculated ARDI relative to
the Cooper regimen (1979) as before. Because dose reduc-
tions and treatment delays were largely unreported they con-
fined their analysis to projected rather than received doses. In
order to incorporate melphalan-containing regimens in the
analysis they needed to make the additional assumption that
40 mg of cyclophosphamide was equivalent to 1 mg of mel-
phalan. They also assigned a dose intensity of 0 to 'missing
drugs' for regimens containing only one or two of the three
drugs in standard CMF and included 'no treatment' arms
(with an ARDI of 0) in their analysis. Once again they were
able to see a positive linear relationship between ARDI and 3
year RFS. The relationship also held true for differing prog-
nostic sub groups of patients.
This type of analysis has however been extensively crit-
icised (Henderson et al., 1988) because of the requisite
assumptions and for the following reasons: (a) the possible
effect of drug synergy is ignored; (b) inclusion of the 'no
treatment' arms, assuming any effect of adjuvant CMF, will
bias the analysis in favour of a positive relationship; (c) if
analysis is limited to those regimens with CMF (all three
drugs) or CMF and prednisolone and/or vincristine then
there is no obvious correlation between ARDI and RFS.
It should also be emphasised that the results of treatment
with the CMF and CAF type regimens, in both advanced
disease and the adjuvant setting, analysed by Hryniuk are
derived from trials which were not designed to test dose or
dose intensity and their study is thus not a meta-analysis of
many trials designed to test a single treatment variable.
Ovarian cancer
A dose intensity analysis performed by Levin and Hryniuk
(1986), using the same methodology and assumptions, has
demonstrated a positive correlation for planned dose inten-
sity and remission rate in the treatment of advanced ovarian
cancer. There was also a correlation between the relative dose
intensity of cisplatin, but not cyclophosphamide or doxo-
rubicin, and clinical response. This retrospective analysis of
33 first line chemotherapy studies gave further support to the
role of cisplatin as the single most effective agent in the
treatment of this malignancy, with a weighted average median
survival time of 14 months, for regimens not containing
platinum, compared to 24 months for regimens with platinum.
Small cell lung cancer
Klasa et al. (1988) analysed 67 published studies (some of
which were not randomised) reporting the use of chemo-
therapy in limited and extensive stage small cell lung cancer
(SCLC) using methodology similar to that used by Hryniuk.
They attempted to correlate response and median survival
time (MST) against intended dose intensity for each regimen
overall (ARDI) and for each drug within a regimen (RDI)
over the first 6 weeks ofchemotherapy. The regimens used in
their analysis employed multiple agents including cyclophos-
phamide (C), doxorubicin (A), vincristine (V), etoposide (E)
and cisplatin (P). They found a trend (P = 0.07) towards a
positive correlation between ARDI and MST for CAV regi-
mens used in extensive stage disease but not in limited stage
disease. When only randomised studies were considered there
was a positive correlation (P = 0.001) for RDI of doxo-
rubicin with total response rate, but not with survival. A
correlation was seen for the ARDI of etoposide-containing
regimens with overall remission rate and survival in extensive
stage disease only. There were, however, no correlations
whatever with ARDI or RDI and outcome in limited stage
disease for any regimen type. Again, this analysis may be
flawed in that most published studies contain little inform-
ation of actual drug doses delivered. They also only used
intended dose intensity over a relatively short period at the
start of chemotherapy usually because of the reduction in
dose intensity that occurs during radiotherapy. They ignored
the possible influence of radiotherapy on outcome and total
drug dose was not considered. Again it was assumed in the
calculation of ARDI that the component agents have equiva-
lent anti-tumour activity and drug scheduling and inter-
actions were not accounted for. Because of the capping of
vincristine dosages they were also obliged to exclude this
agent from the analysis. They report however, that the most
consistent finding throughout the analysis was the dose-
response effect of doxorubicin.
Lymphomas andmyeloma (within-study analyses)
Carde et al. (1983) carried out a dose-response analysis of
MOPP chemotherapy within a single study of 132 patients
with Hodgkin's disease. They performed multivariate analysis
of 21 clinical variables and studied 40 dose-time variables.
By stepwise regression analysis, only the presence of B-
symptoms and the mean three cycle rate of drug delivery
significantly influenced complete remission rate. The dose
intensity effect in their study was also independent of otherDOSE INTENSITY IN CANCER CHEMOTHERAPY 791
variables (excluding the possibility that lower drug delivery
had a negative effect on remission rate because this group of
patients had more poor prognostic factors). Their study fur-
ther suggested that high dose intensity was most critical in
patients with B-symptoms and exerted its effect very early
during the course of chemotherapy. Lagarde (1989) also
found that a high dose intensity improved the rate and
duration of complete remission in a study of 95 patients with
Hodgkin's disease treated with cyclophosphamide, vinblast-
ine, procarbazine and prednisolone.
A multivariate analysis of 115 previously untreated pa-
tients with advanced stage diffuse large cell lymphoma
(Kwak et al., 1988) has also suggested that dose intensity of
adriamycin and overall dose intensity were significant deter-
minants of outcome.
Palmer (1988) retrospectively analysed the dose intensity of
melphalan and prednisolone (intended doses: 9 mg m2 o.d.
and 50 mg b.d. for 4 days, every 4 weeks) in 93 evaluable
patients presenting with myeloma using the method of
Hryniuk and Bush (1984). The ARDI (relative to protocol)
of the combination ranged from 0.33 to 1.02 and patients
were stratified into three categories according to ARDI: low,
intermediate and high, median survivals being 33, 40 and 46
months respectively. However, despite this positive correla-
tion between survival and overall dose intensity, there was no
correlation between ARDI and antitumour effect (as assessed
by reduction in paraprotein levels). It was also found, sur-
prisingly, that the RDI of prednisolone rather than mel-
phalan correlated most closely with survival. This study may,
however, be criticised in that patients who died (30) or who
developed disease progression (12) before nine months were
excluded from the analysis.
Retrospective total dose analysis
Breast cancer
Bonadonna and Valagussa (1981) performed a retrospective
analysis of two of the early trials of adjuvant CMF in breast
cancer. For each patient they calculated the total dose
administered and expressed this as a percentage of the
'optimal' dose which would have been given if no dose
reductions or delays had occurred. They found that patients
given >85% of optimal dose had a significantly better
disease-free interval (DFI) and overall survival (Bonadonna
et al., 1985) than those given <65% of the intended dose.
However, this apparent dose response effect may have been
influenced by other prognostic variables such as age, perfor-
mance status (Brufman et al., 1983) and early discontinuation
of treatment because of recurrence (resulting in artificially
inferior DFI) in the low dose group. The methodological
problems involved in examining a total dose-outcome rela-
tionship were reviewed by Redman et al. (1983). The large
number of adjuvant CMF trials (summarised in Henderson,
1988) provide conflicting evidence concerning the effect of
total dose on survival.
Dose escalating studies
There are many published reports where phase I/II regimens
using escalating or very high dose treatment (often supported
by marrow rescue or colony-stimulating factors) have demon-
strated improved remission rates over that expected from
'standard' treatment. Survival advantages have also been
reported in the treatment of haematological malignancies by
this approach (see review by Armitage, 1989). Gulati (1988)
has reported a disease free survival advantage for a group of
patients with poor prognosis large cell lymphoma treated
with high dose cyclophosphamide and radiotherapy sup-
ported by autologous bone marrow transplantation (ABMT)
after achieving CR following induction chemotherapy (79%
at 49 + months) compared to 5 months in those patients
who had ablative therapy + ABMT at relapse after induc-
tion treatment. Others have shown that high dose therapy
+ ABMT can achieve complete remissions and prolonged
survival (38% at 2 years, compared to <20% after standard
salvage chemotherapy) in relapsed Hodgkin's disease (Jagan-
nath, 1989). Whether it is possible to bridge the gulf between
the encouraging results of dose escalation in lymphomas to
solid tumours has been the subject of much effort.
In a phase I/II study of 26 patients with advanced breast
cancer Jones et al. (1987) used within-patient dose escalation
of doxorubicin at a starting dose of 25 or 30 mg m-2 for 3
days every 4 weeks. They demonstrated an overall response
rate of 85% (95% confidence intervals 65-96%) with a 38%
CR rate (half of which were pathologically confirmed). Inter-
estingly, although the reported remission rate was high, the
median dose of doxorubicin delivered during this study was
99 mg m-2 every 4 weeks which in fact is almost identical to
the conventional maximum recommended dose of 75 mg m-2
3-weekly (doses which are generally reported to produce
remission rates of around 40% (Tormey, 1975)). This
difference may result from scheduling differences from other
studies or because the maximally tolerated dose for each
individual patient was used.
Bronchud et al. (1989) reported a dose-escalating study
using single agent doxorubicin supported by recombinant
granulocyte colony stimulating factor in the treatment of
women with advanced breast cancer. They employed a 2-
weekly cycle starting at 75 mg m-2 escalating up to
150mgm2. The overall response rate was 80%. All seven
patients responded at the two highest dose levels. Non-
haematological toxicity was dose limiting.
The use of very high doses of drugs supported by
autologous or allogeneic bone marrow transplantation has
been shown to produce remissions after failure of standard
therapy for solid tumours. Generally, however, such remis-
sions are not prolonged and any effect on survival is uncer-
tain. Antman and Gale (1988) have reviewed the role of high
dose chemotherapy supported by autologous bone marrow
support in 326 women with breast cancer. Response rates
and survival in women with refractory breast cancer were
generally low and remissions short-lived. In previously unt-
reated patients response rates were higher (CR rate 56%, OR
rate 72%) with longer remissions of 19-55 months. How-
ever, the group who responded most favourably are those
who showed an initial response to induction therapy followed
by high dose chemotherapy and autologous bone marrow
rescue with CR and OR rates of 71% and 91% respectively.
Treatment mortality was 5-20%.
Randomised studies ofdose and dose intensity
Dose-response studies
There are relatively few studies which have set out to pro-
spectively evaluate dose response in a randomised, controlled
manner. Most of these studies contain treatment arms which
differ in total drug amount administered over the same time.
It is therefore difficult to ascertain whether total dose or dose
intensity were the important determinants of outcome. Ran-
domised studies of dose are listed in Table I but it is worth-
while considering some of them in more detail.
One of the earliest studies of dose response was made in
childhood acute lymphoblastic leukaemia where Pinkel (1971)
showed that remission duration was significantly prolonged
(15 vs 6 months) in children given 'full' rather than 'half'
doses of four drug maintainance therapy. However, in a
larger study (van Eys, 1989) no difference in outcome was
seen for the higher dose arm. Another study (Samson, 1984)
revealed that patients with testicular cancer fared better at a
higher dose level of cisplatin with an improved CR rate and
survival. The dose-response effect of cisplatin in germ cell
tumours has recently been confirmed by Ozols (1988),
although in this study the waters were muddied by the
addition of etoposide in the higher dose arm.
In a study (Cohen, 1977) of 31 patients with previously792 D.J. DODWELL et al.
Table I Prospective randomised studies of dose and dose intensity
Year Author Tumour No. Drugs Dose(mg m2 per cycle) Outcome (low vs high dose)
1984 Samson Testicular 114 Cisplatin 75 vs 120 (4 wkly) CR 43% vs 63% (P = 0.03)
(vinb & bleo) survival advantage in high dose arm
1987 Ozols Non-semin. 52 Cisplatinb 100, 0.3 vs CR 67% vs 88% (P = 0.14)
germ cell vinb (& bleo) 200, 0.2 (3 wkly)b DFS 33% vs 68% at 4 years (P = 0.02)
median survival 30 vs >48 months
1971 Pinkel ALL in CR 42 MP, mtx 350, 20, 200 & 1 vs median remission duration 6 vs 15 months
cyclo & vcr 175, 10, 100 & 0.5 (wkly)
1989 van Eys ALL in CR 434 MP and mtx not givenc no difference in outcome
(vcr & pred)
1986 Carmo-Pereira breast 48 Doxorubicin 35 (8 cycles) vs OR 25% vs 58% (duration 7 vs 14 months)
70 (16 cycles) (3 wkly) significant survival advantage
1987 Hortobagyi breast 59 Cyclo, doxo & 500, 50 & 1000 vs no difference in OR, response duration or
SFU 1200-1800, 70-100 & survival (subsequent analysis revealed similar
2500 (3 wkly) delivered dose intensities in the two arms)
1988 Tannock breast 133 Cyclo, mtx & 300, 20 & 300 vs 600, OR 11% vs 30% (P = 0.03) median survival
5FU 40 & 600 mg (3 wkly)b 12.8 vs 15.6 months (P = 0.026)'
1989 Andrien breast 91 Epirubicin 50 vs 100 (3 wkly) OR 40% vs 67% (P<0.025) but no survival
(cyclo & SFU) advantage
1977 Cohen SCLC 329 Cyclo, CCNU 1000, 50 & 120 vs 2000, OR 45% vs 96% (P<0.05) median
& mtx 100 & 180 (6 wks)d survival 5 vs 10.5 months
1985 Figueredo SCLC 103' Doxorubicin 50, 1000 vs 60, no difference in CR rate or duration
cyclo and (vcr) 1500 (3 wkly)e
1986 Wolff rec. SCLC 79 Etoposide 300 vs 600 vs 900" only 4 responses altogether, no difference
between treatment arms
1986 Klastersky NSCLC 241 Cisplatin 60 vs 120 (3-4 wkly) Or 25% vs 29% (P = n.s.) no survival
(etoposide) difference
1981 Woods head & neck 72 Mtx 50 vs 500 vs 5000 mg (wkly) no difference in response or survival
Doxo, doxorubicin; pred, prednisolone; vcr, vincristine; SCLC, small cell lung cancer; mtx, methotrexate; rec., recurrent; SFU, 5-fluorouracil;
NSCLC, non-small cell lung cancer; cyclo, cyclophosphamide; OR, overall response rate; bleo, bleomycin; CR, complete remission rate; vinb,
vinblastine; MP, mercaptopurine.
'Retreated on haemotological recovery. bHigh dose arm also received etoposide (500 per cycle). cHigh doses to keep WBC 1,500-3,000, standard
doses to keep WBC 3,000-4,500. dDosesonlyescalated between arms for thefirst six weeks (CCNU given 6 weekly, cyclophosphamide 3 weekly and
MTX twice weekly). eEscalating to 2,250 in subsequent courses. f34 limited and 69 extensive stage disease. e27 extensive, 5 local disease. hWith dose
escalation ifpossible. 'Survival difference not significant (P = 0.12) when adjusted forchance imbalance between two arms for time from first relapse
to randomisation. JDrugs in brackets at the same doses between treatment arms.
untreated small cell lung cancer randomisation was made
between 'high' or low doses of the combination CCNU,
cyclophosphamide and methotrexate. Median survival of the
high dose group was 10 months compared with 5 months for
patients treated with a low dose regimen. The low dose
treatment contained 500 mg m-2 of cyclophosphamide, a
dose which would now be considered to be suboptimal. In a
more recent trial (Figueredo, 1985) among 103 patients (ran-
domised to receive 1 or 1.5 gm2 of cyclophosphamide in
combination with doxorubicin and vincristine every 3 weeks)
no differences were seen in response rate or survival.
Wolff et al. (1986) evaluated the dose-response relation-
ships of etoposide in patients with recurrent small cell lung
cancer. They used three dose levels of intravenous etoposide
300, 600 and 900mgm2; 79 patients were treated, divided
equally between the three dose levels and despite substan-
tially increased toxicity in the higher dose arm only four
partial responses were seen in all patients and they were
distributed amongst all dose levels.
In the treatment of advanced non-small cell lung cancer
Klastersky et al. (1986) conducted a randomised trial com-
paring a high (120 mg m 2) or standard (60 mg m-2) dose of
cisplatin in combination with etoposide. They reported a
25% objective response rate in the standard arm and 29% in
the high dose arm with no improvement in survival.
Hortobagyi (1987) reported the results of a trial comparing
conventional and escalating doses of fluorouracil, dox-
orubicin and cyclophosphamide (FAC) in patients with
previously untreated advanced breast cancer. The group of
patients receiving escalating dose treatment were further ran-
domised to receive chemotherapy within a protected environ-
ment and with the administration of prophylactic antibiotics
or in a standard hospital room. Dose escalations were made
to 100 mg m-2 of doxorubicin and 1800 mg m-2 of cyc-
lophosphamide. There were no significant differences in res-
ponse rates or survival between high and standard dose
treatments. Subsequent analysis has, however, revealed that
delivered dose intensities were similar in the two arms.
Dose intensity studies
One of the few 'positive' studies was that of Carmo-Pereira et
al. (1986), who performed a randomised study comparing
two differing dose intensities of single agent doxorubicin for
the treatment of patients with metastatic breast cancer.
Forty-eight patients were randomised to receive either
70 mg m-2 every 3 weeks for eight courses or 35 mg m-2
every 3 weeks for 16 courses. Total dose was therefore the
same. There was a response rate of 58% in the more dose
intensive arm compared to 25% in the less intensive arm.
Response duration and survival were also significantly
superior at the higher dose intensity. It may be considered,
however, that the less intensive treatment was suboptimal.
This highlights an important methodological problem, in that
if cytotoxic drug treatment has any effect over no treatment,
it will always be possible to choose a small enough dose level
to be indistinguishable from no treatment and therefore to be
able to demonstrate a dose response effect. Preliminary
analysis of a dose intensity study in advanced ovarian cancer
where 6 months therapy with a quadruple drug regimen at a
high relative dose intensity were compared with 12 months of
less intensive treatment (so the total drug doses were iden-
tical) has demonstrated a significantly higher overall response
rate in the higher dose arm (D. Crowther, personal com-
munication). It is too early, however, to make any comment
about response duration or survival.DOSE INTENSITY IN CANCER CHEMOTHERAPY 793
It can be seen that the few randomised dose studies that
are available provide conflicting evidence concerning the cor-
relation between increased dose or dose intensity and an
improved response rate and survival.
Future studies
How may studies be planned in order to address these impor-
tant and topical questions? Coppin (1987) has elegantly
reviewed the problems associated with the description and
presentation of drug delivery. Dose and dose intensity
although obviously closely linked are variables which need to
be addressed separately by prospective randomised studies.
Clearly the initial requirement for clinicians attempting to
analyse dose intensity within a particular protocol is to
record details of actual doses delivered, dose reductions made
and treatment delays that occurred. Computer databases
need the facility to store this information. Although dose
delays to allow haematological recovery are inevitable, the
rationale for dose reduction is not established. A recent
analysis (N. Thatcher, personal communication) of toxicity
occurring within intensive regimens for the treatment of
SCLC has established that of 17 infective deaths occurring
after a total of 1,966 cycles of chemotherapy, given to 383
patients, only four occurred in those patients previously
experiencing life threatening infection and were potentially
avoidable by dose reduction. Why, therefore, should doses,
be reduced? It would certainly simplify dose-response
analysis if no dose reductions were made.
The scheduling of cytotoxic drugs may also differ between
regimens where dose and dose intensity are the same and
must be considered when two studies are compared. Valdi-
vieso (1984) reported a study of 100 patients with NSCLC.
They were randomised to receive doxorubicin at 20mgm-2
weekly or 60mgm-2 3-weekly with ftorafur, cyclophospha-
mide and cisplatin (at the same dose and schedule). Response
rate, response duration and survival were all greater in the
group treated with weekly doxorubicin. Etoposide has also
been shown to be highly schedule dependent in SCLC (Slevin
et al., 1989).
In summary therefore the hypotheses generated by retro-
spective analyses regarding dose intensity and total dose have
yet to be proven. Further clinical trials are required to
elucidate the role of dose intensive regimens in the treatment
of malignant disease. As the major dose-limiting toxicity of
cytotoxic drug regimens is usually haematological it is likely
that the advent ofcolony stimulating factors will enable us to
substantially increase the dose intensity of cytotoxic regimens
and provide us with the methods to answer these questions in
prospective clinical trials.
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